Anti-tumor necrosis factor-alpha-loaded microspheres as a prospective novel treatment for crohn's disease fistulae

Tissue Engineering - Part C: Methods

Volumn 16, Issue 5, 2010, Pages 855-864

  Foong, Keen Shawn ^a   Patel, Rishni ^a   Forbes, Alastair ^a   Day, Richard M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOACTIVITY; BLENDING; CELL CULTURE; CYTOTOXICITY; DRUG DELIVERY; ENCAPSULATION; GLYCOPROTEINS; MACROPHAGES; MICROSPHERES; PHASE SEPARATION; SCANNING ELECTRON MICROSCOPY; SOLUTIONS; TISSUE ENGINEERING; TUMORS;

ANTI-TUMORS; AQUEOUS SOLUTIONS; BIOLOGICAL ACTIVITIES; CROHN'S DISEASE; CURRENT MODE; CYTOTOXIC ACTIVITIES; CYTOTOXICITY ASSAYS; DRUG DELIVERY DEVICES; ENCAPSULATION EFFICIENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST MIGRATION; HIGH YIELD; IN-CELL; IN-VITRO; LACTATE DEHYDROGENASE; NOVEL TECHNIQUES; PHOSPHATE-BUFFERED SALINES; POLY LACTIDE-CO-GLYCOLIDE; POROUS MICROSPHERES; RAPID FABRICATION; SCAFFOLDS FOR TISSUE ENGINEERING; THERAPEUTIC PEPTIDES; THERMALLY INDUCED PHASE SEPARATION; TIPS PROCESS; TUMOR NECROSIS FACTOR ALPHA; ZERO ORDER KINETICS;

ANTIBODIES;

FISTULA;

INFLIXIMAB; LACTIC ACID; MICROSPHERE; MONOCLONAL ANTIBODY; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL LINE; CROHN DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOLOGY; PROSPECTIVE STUDY; RECTUM FISTULA; SCANNING ELECTRON MICROSCOPY;

ANTIBODIES, MONOCLONAL; CELL LINE; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LACTIC ACID; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; POLYGLYCOLIC ACID; PROSPECTIVE STUDIES; RECTAL FISTULA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957357041     PISSN: 19373384     EISSN: 19373392     Source Type: Journal    
DOI: 10.1089/ten.tec.2009.0599     Document Type: Article

References (34)

1. Schwartz, D.A., Pemberton, J.H., and Sandborn, W.J. Diagnosis and treatment of perianal fistulas in Crohn's disease. Ann Intern Med 135, 906, 2001.
2. Scott, H.J., and Northover, J.M. Evaluation of surgery for perianal Crohn's fistulas. Dis Colon Rectum 39, 1039, 1996.
3. Sandborn, W.J. Clinical perspectives in Crohn's disease. Moving forward with anti-TNF-alpha therapy: current needs and future treatments. Rev Gastroenterol Disord 7(Suppl 2), S23, 2007.
4. Present, D.H., Rutgeerts, P., Targan, S., Hanauer, S.B., Mayer, L., and van Hogezand, R.A. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340, 1398, 1999.
5. Sands, B.E., Anderson, F.H., Bernstein, C.N., Chey, W.Y., Feagan, B.G., and Fedorak, R.N. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 350, 876, 2004.
6. Baert, F., Noman, M., Vermeire, S., Van, A.G., Carbonez, A., and Rutgeerts, P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348, 601, 2003.
7. Hanauer, S.B., Wagner, C.L., Bala, M., Mayer, L., Travers, S., and Diamond, R.H. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2, 542, 2004.
8. Lichtenstein, G.R. Incorrect cost of infliximab in fistulizing Crohn's disease. Gastroenterology 127, 691, 2004.
9. Bickston, S.J., Lichtenstein, G.R., Arseneau, K.O., Cohen, R.B., and Cominelli, F. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastro-enterology 117, 1433, 1999.
10. Keane, J., Gershon, S., Wise, R.P., Mirabile-Levens, E., Kasznica, J., and Schwieterman, W.D. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345, 1098, 2001.
11. Keshaw, H., Foong, K.S., Forbes, A., and Day, R.M. Perianal fistulae in Crohn's disease: current and future approaches to treatment. Inflamm Bowel Dis 2009 (In press).
12. Blaker, J.J., Pratten, J., Ready, D., Knowles, J.C., Forbes, A., and Day, R.M. Assessment of antimicrobial micro-spheres as a prospective novel treatment targeted towards the repair of perianal fistulae. Aliment Pharmacol Ther 28, 614, 2008.
13. Keshaw, H., Georgiou, G., Blaker, J.J., Forbes, A., Knowles, J.C., and Day, R.M. Assessment of polymer=bioactive glass-composite microporous spheres for tissue regeneration applications. Tissue Eng Part A 15, 1451, 2009.
14. Weerakody, R., Fagan, P., and Kosaraju, S.L. Chitosan mi-crospheres for encapsulation of alpha-lipoic acid. Int J Pharm 357, 213, 2008.
15. Keshaw, H., Thapar, N., Burns, A., Mordan, N., Knowles, J.C., Forbes, A., and Day, R.M. Microporous collagen spheres produced via thermally induced phase separation for tissue regeneration. Acta Biomaterialia 2009 (In press).
16. Shive, M.S., and Anderson, J.M. Biodegradation and bio-compatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 28, 5, 1997.
17. Lu, L., Peter, S.J., Lyman, M.D., Lai, H.L., Leite, S.M., and Tamada, J.A. In vitro and in vivo degradation of porous poly (d,l-lactic-co-glycolic acid) foams. Biomaterials 21, 1837, 2000.
18. Ternant, D., Mulleman, D., Degenne, D., Willot, S., Guil-laumin, J.M., Watier, H., and Goupille, P. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit 28, 169, 2006.
19. Du, L., Cheng, J., Chi, Q., Qie, J., Liu, Y., and Mei, X. Biodegradable PLGA microspheres as a sustained release system for a new luteinizing hormone-releasing hormone (LHRH) antagonist. Chem Pharm Bull 54, 1259, 2006.
20. Moioli, E.K., Hong, L., Guardado, J., Clark, P.A., and Mao, J.J. Sustained release of TGFbeta3 from PLGA microspheres and its effect on early osteogenic differentiation of human mesenchymal stem cells. Tissue Eng 12, 537, 2006.
21. Wang, J., Chua, K.M., and Wang, C.H. Stabilization and encapsulation of human immunoglobulin G into biodegradable microspheres. J Colloid Interface Sci 271, 92, 2004.
22. Day, R.M., Maquet, V., Boccaccini, A.R., Jérôme, R., and Forbes, A. In vitro and in vivo analysis of macroporous biodegradable poly(D,L-lactide-co-glycolide) scaffolds containing bioactive glass. J Biomed Mater Res A 75, 778, 2005.
23. Cao, Y., Mitchell, G., Messina, A., Price, L., Thompson, E., and Penington, A. The influence of architecture on degradation and tissue ingrowth into three-dimensional poly(lactic co-glycolic acid) scaffolds in vitro and in vivo. Biomaterials 27, 2854, 2006.
24. Blaker, J.J., Knowles, J.C., and Day, R.M. Novel fabrication techniques to produce microspheres by thermally induced phase separation for tissue engineering and drug delivery. Acta Biomater 4, 264, 2008.
25. Sah, H. Stabilization of proteins against methylene chloride= water interface-induced denaturation and aggregation. J Controlled Release 58, 143, 1999.
26. Jeyanthi, R., Thanoo, B.C., Metha, R.C., and DeLuca, P.P. Effect of solvent removal technique on the matrix characteristics of polylactide=glycolide microspheres for peptide delivery. J Controlled Release 38, 235, 1996.
27. Kim, T.K., Yoon, J.J., Lee, D.S., and Park, T.G. Gas foamed open porous biodegradable polymeric microspheres. Bio-materials 27, 152, 2006.
28. Crotts, G., and Park, T.G. Preparation of porous and non-porous biodegradable polymeric hollow microspheres. J Controlled Release 35, 91, 1995.
29. Hong, Y., Gao, C., Shi, Y., and Shen, J. Preparation of porous polylactide microspheres by emulsion-solvent evaporation based on solution induced phase separation. Polym Adv Technol 16, 622, 2005.
30. Del, G.P., Colombo, P., Colombo, G., Russo, P., and Sonvico, F. Mechanisms of formation and disintegration of alginate beads obtained by prilling. Int J Pharm 302, 1, 2005.
31. Maquet, V., Boccaccini, A.R., Pravata, L., Notingher, I., and Jerome, R. Porous poly(alpha-hydroxyacid)=bioglass composite scaffolds for bone tissue engineering. I: preparation and in vitro characterisation. Biomaterials 25, 4185, 2004.
32. Dunne, M., Corrigan, I., and Ramtoola, Z. Influence of particle size and dissolution conditions on the degradation properties of polylactide-co-glycolide particles. Biomaterials 21, 1659, 2000.
33. Liang, C.C., Park, A.Y., and Guan, J.L. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2, 329, 2007.
34. Di Sabatino, A., Pender, S.L., Jackson, C.L., Prothero, J.D., Gordon, J.N., Picariello, L., Rovedatti, L., Docena, L., Mon-teleone, G., Rampton, D.S., Tonelli, F., Corazza, G.R., and MacDonald, T.T. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology 133, 137, 2007.